Preparation and characterization of novel microparticles based on poly(3-hydroxybutyrate-co-3-hydroxyoctanoate)

Zhang, Chan; Dong, Yuefeng; Li, Zhao

doi:10.3109/02652048.2013.799241

Cited by 4 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…And P(HB-HO) is used as a drug carrier because of its biodegradation (Guo et al, 2009) and biocompatibility (Dong et al, 2008). P(HB-HO) microspheres (Zhang et al, 2014) and folate-targeted NPs (Zhang et al, 2010) were prepared in our previous study.…”

Section: Introductionmentioning

confidence: 99%

Quantification of DOX bioavailability in biological samples of mice by sensitive and precise HPLC assay

Zhang

Dong³

et al. 2015

Pharmaceutical Biology

Self Cite

View full text Add to dashboard Cite

Results: The t 1/2 values of DOX/P(HB-HO) NPs and DOX/FA-PEG-P(HB-HO) NPs were 2.7-and 3.5-times higher than that of free DOX. No significant difference (p40.05) was found in C max between the NPs and free DOX. The T max values of the two NPs were prolonged from 0.25 to 1 h. The AUC 0-t values were 1.55-and 3.05-folds higher than that of free DOX, and MRT increased to 15.99 h for DOX/P(HB-HO) NPs and 25.14 h for DOX/FA-PEG-P(HB-HO) NPs. For DOX/FA-PEG-P(HB-HO) NPs, the DOX content in the tumors were 10.81-and 3.33-times higher than those for free DOX and DOX/P(HB-HO) NPs at 48 h, respectively. Discussion and conclusions: DOX/FA-PEG-P(HB-HO) NPs displayed reduced cardiac toxicity and improved bioavailability. Moreover, the NPs exhibited a significant extent of DOX accumulation in the tumors, thus suggesting that folate-targeted NPs could effectively transport into HeLa tumors with satisfying targeting.

show abstract

Section: Introductionmentioning

confidence: 99%

Quantification of DOX bioavailability in biological samples of mice by sensitive and precise HPLC assay

Zhang

Dong³

et al. 2015

Pharmaceutical Biology

Self Cite

View full text Add to dashboard Cite

show abstract

“…P(R)-HB [93][94][95][96][97], and bacterial copolymers such as P(3HB-co-4HB) [98][99][100], PHBV [101][102][103] or PHBH and derivatives [104][105][106], have been used for the elaboration of self-assembled systems such as DDSs, tissue engineering scaffolds and implants [107][108][109][110]. Those polymers have been chosen for their biodegradability and biocompatibility.…”

Section: Chemically Modified Bacterial Phb-based (Co)polymersmentioning

confidence: 99%

Advances in drug delivery systems based on synthetic poly(hydroxybutyrate) (co)polymers

Barouti

Jaffredo

Guillaume

2017

Progress in Polymer Science

View full text Add to dashboard Cite

International audienceWithin the general context of nanomedicine, drug delivery systems based on polymers have sparkeda rapidly growing interest and raised many efforts to tackle various diseases, among which cancer.Polyester-based nanoparticulate drug delivery systems, including polymer-drug conjugates andamphiphilic block copolymers, represent a major class with promising outcomes, especially for thosederived from poly(3-hydroxybutyrate) (PHB). This review describes recent advances in drug delivery systemsdesigned from the self-assembly of synthetic (co)polymers derived from PHB. The various strategiesfor the synthesis of PHB-conjugates, PHB/poly(ethylene glycol) (PEG) and other PHB-based copolymersare first summarized. Nanoparticles, micelles, microparticles, and hydrogels elaborated from these(co)polymers following various preparation methods, along with their exploitation in the encapsulationand release of various therapeutic agents, are next detailed. Finally, we discuss the synthetic challenges,drug delivery outlooks, and perspectives of PHB-based drug delivery systems. Engineered nano-scaledmaterials based on PHB self-assembled systems are thus anticipated to emerge as a valuable platformfor original drug delivery systems

show abstract

“…Polymers may also play an important role in preparing various drug formulations. Poly(3-hydroxybutyrateco-3-hydroxyoctanoate) [P(HB-HO)] possessing good physical-chemical and biological properties is derived from Sinorhizobium fredii (Zhao et al, 2006), and it can be utilized as drug carrier (Zhang et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

Folate-decorated poly(3-hydroxybutyrate-co-3-hydroxyoctanoate) nanoparticles for targeting delivery: optimization andin vivoantitumor activity

Zhang

2015

Drug Delivery

Self Cite

View full text Add to dashboard Cite

Context: Doxorubicin (DOX)-loaded folate-targeted poly(3-hydroxybutyrate-co-3-hydroxyoctanoate) [P(HB-HO)] nanoparticles [DOX/FA-PEG-P(HB-HO) NPs] have potential application in clinical treatments for cervical cancer due to specific affinity of folate and folate receptor in HeLa cells. Objective: The aim of this study was to develop an optimized formulation for DOX/FA-PEG-P(HB-HO) NPs, and investigate the targeting and efficacies of the nanoparticles. Materials and methods: DOX/FA-PEG-P(HB-HO) NPs were prepared by W 1 /O/W 2 solvent extraction/evaporation method, and an orthogonal experimental design [L 9 ( 3 4 )] was applied to establish the optimum conditions. The physico-chemical characteristics, microscopic observation and in vivo antitumor study of the nanoparticles were evaluated. Results: The optimum formulation was obtained with DOX 10% (w/v), FA-PEG-P(HB-HO) 6.5% (w/v), PVA 3%(w/v) and oil phase/internal water phase volume ratio of 3/1. The size distribution, drug loading and encapsulation efficiency of the optimized nanoparticles were 150-350 nm, 29.6 ± 2.9% and 83.5 ± 5.7%, respectively. In vitro release study demonstrated that 80% of the drug could release from the nanoparticles within 11 days. Furthermore, in vitro microscopic observation and in vivo antitumor study showed that DOX/FA-PEG-P(HB-HO) NPs could inhibit HeLa cells effectively, and the tumor inhibition rate (TIR) in vivo was 76.91%. Discussion and conclusions: DOX/FA-PEG-P(HB-HO) NPs have been successfully developed and optimized. In vitro drug release study suggested a sustained release profile. Moreover, DOX/FA-PEG-P(HB-HO) NPs could effectively inhibit HeLa cells with satisfying targeting, and reduce side effects and toxicity to normal tissues. DOX/FA-PEG-P(HB-HO) NPs were superior in terms of inhibiting HeLa tumor over non-targeted formulations therapy. KeywordsDoxorubicin, folate-targeted nanoparticles, in vivo antitumor activity, orthogonal design, poly(3-hydroxybutyrateco-3-hydroxyoctanoate)History

show abstract

Preparation and characterization of novel microparticles based on poly(3-hydroxybutyrate-co-3-hydroxyoctanoate)

Cited by 4 publications

References 24 publications

Quantification of DOX bioavailability in biological samples of mice by sensitive and precise HPLC assay

Quantification of DOX bioavailability in biological samples of mice by sensitive and precise HPLC assay

Advances in drug delivery systems based on synthetic poly(hydroxybutyrate) (co)polymers

Folate-decorated poly(3-hydroxybutyrate-co-3-hydroxyoctanoate) nanoparticles for targeting delivery: optimization andin vivoantitumor activity

Contact Info

Product

Resources

About